Many people using GLP-1s for weight loss stop treatment too soon, research shows, and results are not one-size-fits-all

Demand for GLP-1 drugs like Wegovy has surged, but many patients may not be adhering to their weight-loss treatment plan. An analysis of health insurance claims revealed that the majority of people using GLP-1 medications did not stay on their treatment plan for the recommended duration. About 30% dropped out before reaching the targeted dose. Impatience with results and side effects were cited as reasons for discontinuation. The study emphasized the importance of frequent follow-up visits and wraparound support for patients. The high cost of the medications was also noted as a potential deterrent. Another report highlighted the extended benefits of long-term consistent treatment with GLP-1 drugs.